Phenotypes associated with this allele

• Allele Symbol: Tg(Pdx1-cre/Esr1*)#Dam
• Allele Name: transgene insertion, Douglas A Melton
• Allele ID: MGI:5008261
• Summary: 6 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor^+ Tg(Pdx1-cre/Esr1*)#Dam/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:5581814
cn2	Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^tm1(Kcnj11*V59M)Fmas Tg(Pdx1-cre/Esr1*)#Dam/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:5581815
cn3	Nkx2-2^tm2.1Suss/Nkx2-2^tm2.1Suss Gt(ROSA)26Sor^tm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor^+ Tg(Pdx1-cre/Esr1*)#Dam/0	involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA * SJL	MGI:5297840
cn4	Senp1^tm1.1Eyeh/Senp1^tm1.1Eyeh Tg(Pdx1-cre/Esr1*)#Dam/0	involves: C57BL/6	MGI:5883578
cn5	Smad7^tm1Gkg/Smad7^tm1Gkg Tg(Pdx1-cre/Esr1*)#Dam/0	involves: C57BL/6 * CBA	MGI:5567933
cn6	Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^+ Tg(Pdx1-cre/Esr1*)#Dam/0	involves: C57BL/6 * CBA	MGI:5581813

Genotype
MGI:5581814

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Kcnj11*V59M)Fmas}/Gt(ROSA)26Sor⁺; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

hyperglycemia ( J:210493 )

• severe in tamoxifen-treated mice without beta-cell apoptosis

Genotype
MGI:5581815

cn2

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^{tm1(Kcnj11*V59M)Fmas}; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

endocrine/exocrine glands

abnormal pancreatic beta cell physiology ( J:210493 )

• beta cells from tamoxifen-treated mice exhibit signs of DNA damage and apoptosis compared to control mice but to a lesser extent than in mice lacking Gt(ROSA)26Sor^{tm1(Kcnj11*V59M)Fmas}

homeostasis/metabolism

hyperglycemia ( J:210493 )

• severe in tamoxifen-treated mice

Genotype
MGI:5297840

cn3

• Allelic Composition: Nkx2-2^tm2.1Suss/Nkx2-2^tm2.1Suss; Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze}/Gt(ROSA)26Sor⁺; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA * SJL

endocrine/exocrine glands

abnormal pancreatic beta cell differentiation ( J:177838 )

• mice treated with tamoxifen at 3 weeks of age exhibit beta cells to alpha cells reprogramming

cellular

abnormal pancreatic beta cell differentiation ( J:177838 )

• mice treated with tamoxifen at 3 weeks of age exhibit beta cells to alpha cells reprogramming

Genotype
MGI:5883578

cn4

• Allelic Composition: Senp1^tm1.1Eyeh/Senp1^tm1.1Eyeh; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: C57BL/6

homeostasis/metabolism

decreased insulin secretion ( J:226392 )

♂ • in vitro, islets isolated from tamoxifen-treated male mice exhibit an impaired glucose and KCl-induced insulin secretory response in a perifusion assay, also shown as a reduced area under the curve (AUC) of the responses to glucose and KCl

♂ • however, the insulin content of mutant islets is unchanged

impaired glucose tolerance ( J:226392 )

♂ • however, insulin tolerance is similar to that in control littermates

♂ • tamoxifen-treated male mice exhibit an exaggerated glucose excursion in response to an oral glucose challenge

endocrine/exocrine glands

decreased insulin secretion ( J:226392 )

♂ • in vitro, islets isolated from tamoxifen-treated male mice exhibit an impaired glucose and KCl-induced insulin secretory response in a perifusion assay, also shown as a reduced area under the curve (AUC) of the responses to glucose and KCl

♂ • however, the insulin content of mutant islets is unchanged

Genotype
MGI:5567933

cn5

• Allelic Composition: Smad7^tm1Gkg/Smad7^tm1Gkg; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: C57BL/6 * CBA

endocrine/exocrine glands

abnormal pancreatic beta cell differentiation ( J:198451 )

• reduced immature beta cells at E17.5 in tamoxifen-treated mice

decreased pancreatic alpha cell number ( J:198451 )

• at E17.5 in tamoxifen-treated mice

decreased pancreatic beta cell number ( J:198451 )

• at E17.5 in tamoxifen-treated mice

cellular

abnormal pancreatic beta cell differentiation ( J:198451 )

• reduced immature beta cells at E17.5 in tamoxifen-treated mice

Genotype
MGI:5581813

cn6

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor⁺; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: C57BL/6 * CBA

homeostasis/metabolism

decreased fasting circulating glucose level ( J:210493 )

• in tamoxifen-treated mice

• however, induced hypoglycemia is transient

increased circulating insulin level ( J:210493 )

• in tamoxifen-treated mice

increased oxygen consumption ( J:210493 )

• in tamoxifen-treated mice

endocrine/exocrine glands

abnormal pancreatic beta cell physiology ( J:210493 )

• increased beta cell apoptosis and reduced proliferation in tamoxifen-treated mice

• beta cells from tamoxifen-treated mice exhibit glucotoxicity including increased expression of ER and oxidative stress markers compared to in control cells

• however, GFP- beta cells exhibit increased proliferation and mice treated with a selective inhibitor of calcineurin (tacrolimus; FK-506) or a GLP-1 receptor agonist (liraglutide) exhibit reduced beta cell apoptosis and dysfunction

decreased pancreatic beta cell proliferation ( J:210493 )

• reduced proliferation in tamoxifen-treated mice

• however, GFP- beta cells exhibit increased proliferation

cellular

decreased pancreatic beta cell proliferation ( J:210493 )

• reduced proliferation in tamoxifen-treated mice

• however, GFP- beta cells exhibit increased proliferation